{'fraction_non_alphanumeric': 0.029940119760479042, 'fraction_numerical': 0.007984031936127744, 'mean_word_length': 5.605263157894737, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Liraglutide effects on beta‐cell, insulin sensitivity and glucose effectiveness in patients with stable coronary artery disease and newly diagnosed type 2 diabetes

The aims of the study were to investigate the effects of the GLP‐1 receptor agonist liraglutide as add‐on to metformin on insulin sensitivity (Si) and glucose effectiveness (Sg) in addition to its positive effects on beta‐cell function in overweight/obese patients with coronary artery disease (CAD) and type 2 diabetes mellitus (T2DM).